Kezar Life Sciences (KZR) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases, targeting the immunoproteasome to address multiple chronic inflammatory disorders.

• Lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor in Phase 2a clinical trials for autoimmune hepatitis and previously tested in systemic lupus erythematosus and lupus nephritis.

• No products approved for sale and no revenue from product sales to date; operations funded primarily through equity and debt offerings.

• Substantial resources will be allocated to development, regulatory approval, and potential commercialization of zetomipzomib in the foreseeable future.

Financial performance and metrics

• As of February 3, 2025, the aggregate market value of common stock held by non-affiliates was approximately $44.3 million, based on 7,119,945 shares at $6.22 per share.

• The company qualifies as a "smaller reporting company" under SEC rules, allowing for scaled disclosure requirements.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes, including R&D, administrative expenses, and capital expenditures.

• Pending use, proceeds may be invested in capital preservation instruments such as short-term, interest-bearing obligations and investment-grade instruments.